1. Pink Sheet

Califf Confident Public Trust In US FDA Will Be Rebuilt

 
• By Derrick Gingery

Commissioner nominee strikes an optimistic note as former FDA heads raise concerns about the decrease in agency credibility during the pandemic.

Commissioner Roundtable at CERSI innovation in reg science summit
Acting FDA Commissioner Janet Woodcock and former commissioners Robert Califf, Scott Gottlieb, Margaret Hamburg and Mark McClellan spoke with Takeda R&D President Andy Plump about the future of the FDA during a recent conference. • Source: Screenshot

US FDA Commissioner nominee Robert Califf struck a positive tone about the impact of potentially his and subsequent administrations, stating that in five years public trust in the agency will be restored.

Controversial decisions and political meddling during the coronavirus pandemic have sown doubt about the decisions from the US Food and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

US FDA Requires Opioid Class Labeling Changes Despite Adcomm Advice

 
• By Kate Rawson

Quantitative estimates of the safety risks with opioid pain medication, including the risk of addiction and misuse, must be added to labeling.

US FDA Skips User Fee Increase For More Staff Amid Exodus, Hiring Difficulties

 
• By Derrick Gingery

A calculation used to determine whether the FDA has the staff to handle its workload also was not included in the description of prescription drug user fee calculations.

New US FDA Chief Counsel More Familiar With Trump World Than Food and Drug Law

 
• By Sarah Karlin-Smith

Sean Keveney is largely unknown in the FDA law space, but likely is familiar and connected to the White House given his work on Trump’s antisemitism taskforce.

Will US FDA’s Leadership Rediscover The Value Of Advisory Committees?

 
• By Michael McCaughan

After the abrupt departure of CBER’s director, it seems FDA, and Vinay Prasad in particular, would likely have been well served by hearing from an advisory committee before requesting the suspension in sales of Sarepta’s DMD gene therapy Elevidys.

More from Agency Leadership